XPO1
Exportin-1
As of the edition of 20 October 2026, XPO1 (exportin-1, UniProt O14980) has 3 drugs tested at it and 2 companies on the list, 0 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- O14980
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 19
- Disease areas
- Cancer; Blood and lymph; Immune system; Heart and blood vessels; Urinary and reproductive; Pregnancy and women's health; Digestive system; Hormones
- Registered trials of its drugs
- 191
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Stopped | 2 |
| Total | 3 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Selinexor | Marketed | Phase 4 | Ends 2035 |
| Eltanexor | Stopped | Phase 2 | none listed |
| Verdinexor | Stopped | Phase 1 | none listed |
3 of 3 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 2 |
| Total on the list | 2 |
| Company | Route |
|---|---|
| Karyopharm Therapeutics | Route B |
| Stemline Therapeutics | Route B |
The other 0 companies at XPO1
In the product2 companies in all; 0 are not named here, and no score is.
See the 2 companies at XPO1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.